Continue to site >
Trending ETFs

Franklin Genomic Advancements ETF

Active ETF
HELX
Payout Change
Suspended
Price as of:
$30.7439 -0.2 -0.65%
primary theme
Health Care Sector Equity
HELX (ETF)

Franklin Genomic Advancements ETF

Payout Change
Suspended
Price as of:
$30.7439 -0.2 -0.65%
primary theme
Health Care Sector Equity
HELX (ETF)

Franklin Genomic Advancements ETF

Payout Change
Suspended
Price as of:
$30.7439 -0.2 -0.65%
primary theme
Health Care Sector Equity

Name

As of 10/30/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$30.74

$9.65 M

0.00%

0.50%

Vitals

YTD Return

0.9%

1 yr return

20.6%

3 Yr Avg Return

-16.7%

5 Yr Avg Return

N/A

Net Assets

$9.65 M

Holdings in Top 10

45.9%

52 WEEK LOW AND HIGH

$30.9
$26.08
$33.98

Expenses

OPERATING FEES

Expense Ratio 0.50%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 61.43%

Redemption Fee N/A


Min Investment

Standard (Taxable)

N/A

IRA

N/A


Fund Classification

Fund Type

Exchange Traded Fund


Name

As of 10/30/2024

Price

Aum/Mkt Cap

YIELD

Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.

Exp Ratio

Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.

Watchlist

$30.74

$9.65 M

0.00%

0.50%

HELX - Profile

Distributions

  • YTD Total Return 0.9%
  • 3 Yr Annualized Total Return -16.7%
  • 5 Yr Annualized Total Return N/A
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio -0.32%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annual

Fund Details

  • Legal Name
    Franklin Genomic Advancements ETF
  • Fund Family Name
    Franklin Templeton Group of Funds
  • Inception Date
    Feb 27, 2020
  • Shares Outstanding
    349986
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    US
  • Manager
    Joyce Lin

Fund Description

Under normal market conditions, the Fund invests at least 80% of its net assets in equity securities of companies that are relevant to the Fund’s investment theme of genomic advancements. The Fund invests predominantly in common stock.

Companies relevant to the Fund’s investment theme of genomic advancements are those that the investment manager believes are substantially focused on and/or are expected to substantially benefit from extending and enhancing the quality of human and other life (e.g., animals) by incorporating technological and scientific developments, improvements and advancements in the field of genomics into their business, such as by offering new products or services that rely on genetic engineering, gene therapy, genome analysis, DNA sequencing, synthesis or instrumentation. These companies may include those that research, develop, produce, manufacture or significantly rely on or enable bionic devices, bio-inspired computing, bioinformatics, molecular medicine and diagnostics, pharmaceuticals and agricultural applications of genomics, and related equipment, techniques and processes.

In pursuing the Fund’s investment theme, the investment manager may invest in companies in any economic sector or of any market capitalization and may invest in companies both inside and outside of the United States, including those in developing or emerging markets. Although the Fund may invest across economic sectors, the Fund concentrates its investments in health care related industries. The Fund is a “non-diversified” fund, which means it generally invests a greater proportion of its assets in the securities of one or more issuers and invests overall in a smaller number of issuers than a diversified fund.

In selecting companies that the investment manager believes are relevant to the Fund’s investment theme of genomic advancements, the investment manager seeks to identify, using its own fundamental, “bottom-up” research and analysis, companies positioned to capitalize on disruptive innovation in or that are enabling the further development of the genomic advancements theme in the markets in which they operate. The investment manager’s internal research and analysis leverages insights from diverse sources, including external research, to develop and refine its investment theme and identify and take advantage of trends that have ramifications for individual companies or entire industries. The investment manager also evaluates market segments, products, services and business models positioned to benefit significantly from advancements in genomics relative to broad

securities markets, and seeks to identify the primary beneficiaries of new trends or developments in genomics to select investments for the Fund.

The investment manager may seek to sell a security if: (i) the security reaches its valuation target; (ii) the security reaches its position size limit in the Fund’s portfolio; (iii) the security’s fundamentals deteriorate; (iv) there are adverse policy changes that could affect the security’s outlook; or (v) better investment opportunities become available.

Read More

HELX - Performance

Return Ranking - Trailing

Period HELX Return Category Return Low Category Return High Rank in Category (%)
YTD 0.9% -26.9% 24.4% 93.08%
1 Yr 20.6% 4.2% 63.0% 79.87%
3 Yr -16.7%* -31.5% 11.9% 96.71%
5 Yr N/A* -5.1% 14.4% 49.64%
10 Yr N/A* 0.1% 13.1% 71.43%

* Annualized

Return Ranking - Calendar

Period HELX Return Category Return Low Category Return High Rank in Category (%)
2023 1.1% -12.6% 19.0% 64.15%
2022 -37.9% -53.9% 3.2% 97.37%
2021 9.5% -39.6% 24.2% 21.71%
2020 N/A -13.6% 178.2% N/A
2019 N/A 3.8% 63.8% N/A

Total Return Ranking - Trailing

Period HELX Return Category Return Low Category Return High Rank in Category (%)
YTD 0.9% -26.9% 24.4% 93.08%
1 Yr 20.6% 4.2% 63.0% 79.87%
3 Yr -16.7%* -31.5% 11.9% 96.71%
5 Yr N/A* -5.1% 14.4% N/A
10 Yr N/A* 0.1% 13.1% N/A

* Annualized

Total Return Ranking - Calendar

Period HELX Return Category Return Low Category Return High Rank in Category (%)
2023 1.1% -12.6% 19.0% 80.50%
2022 -37.9% -53.9% 3.7% 97.37%
2021 9.8% -33.9% 26.0% 48.68%
2020 N/A -0.7% 180.6% N/A
2019 N/A 4.6% 63.8% N/A

HELX - Holdings

Concentration Analysis

HELX Category Low Category High HELX % Rank
Net Assets 9.65 M 6.87 M 47.2 B 89.31%
Number of Holdings 59 26 430 75.47%
Net Assets in Top 10 4.37 M 2.12 M 22.1 B 93.08%
Weighting of Top 10 45.94% 18.4% 79.7% 53.46%

Top 10 Holdings

  1. Medpace Holdings Inc 7.21%
  2. Vertex Pharmaceuticals Inc 5.53%
  3. Regeneron Pharmaceuticals Inc 5.35%
  4. Eli Lilly Co 4.98%
  5. Danaher Corp 4.91%
  6. Thermo Fisher Scientific Inc 4.64%
  7. Krystal Biotech Inc 4.48%
  8. Natera Inc 3.41%
  9. AstraZeneca PLC 2.72%
  10. Samsung Biologics Co Ltd 2.72%

Asset Allocation

Weighting Return Low Return High HELX % Rank
Stocks
97.65% 87.34% 106.13% 63.52%
Preferred Stocks
1.98% 0.00% 7.86% 11.95%
Cash
0.38% 0.00% 33.01% 76.73%
Other
0.00% -22.99% 23.24% 88.68%
Convertible Bonds
0.00% 0.00% 0.37% 85.06%
Bonds
0.00% 0.00% 12.39% 89.94%

Stock Sector Breakdown

Weighting Return Low Return High HELX % Rank
Healthcare
89.08% 59.26% 100.00% 98.70%
Basic Materials
7.16% 0.00% 7.16% 0.65%
Real Estate
2.34% 0.00% 5.89% 3.90%
Technology
1.42% 0.00% 22.69% 2.60%
Utilities
0.00% 0.00% 0.00% 85.06%
Industrials
0.00% 0.00% 7.02% 85.71%
Financial Services
0.00% 0.00% 1.60% 90.26%
Energy
0.00% 0.00% 0.00% 85.06%
Communication Services
0.00% 0.00% 9.11% 85.71%
Consumer Defense
0.00% 0.00% 25.73% 86.36%
Consumer Cyclical
0.00% 0.00% 1.92% 86.36%

Stock Geographic Breakdown

Weighting Return Low Return High HELX % Rank
US
93.50% 66.06% 104.41% 52.83%
Non US
4.15% 0.00% 28.87% 42.14%

HELX - Expenses

Operational Fees

HELX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.50% 0.08% 4.48% 86.79%
Management Fee 0.50% 0.03% 1.25% 17.61%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

HELX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 3.50% 5.75% N/A
Deferred Load N/A 1.00% 1.00% N/A

Trading Fees

HELX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 1.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

HELX Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 61.43% 0.00% 238.00% 74.81%

HELX - Distributions

Dividend Yield Analysis

HELX Category Low Category High HELX % Rank
Dividend Yield 0.00% 0.00% 6.24% 88.05%

Dividend Distribution Analysis

HELX Category Low Category High Category Mod
Dividend Distribution Frequency Annual Annual Quarterly Annual

Net Income Ratio Analysis

HELX Category Low Category High HELX % Rank
Net Income Ratio -0.32% -2.54% 1.85% 57.24%

Capital Gain Distribution Analysis

HELX Category Low Category High Capital Mode
Capital Gain Distribution Frequency Annually Semi-Annually Annually

Distributions History

View More +

HELX - Fund Manager Analysis

Managers

Joyce Lin


Start Date

Tenure

Tenure Rank

Feb 25, 2020

2.26

2.3%

Ms. Lin has been a portfolio manager of Franklin Tenmpleton, providing research and advice on the purchases and sales of individual securities, and portfolio risk assessment. She joined Franklin Templeton in 2014. Prior to joining Franklin Templeton in 2014, Ms. Lin was a research associate at Cooke & Bieler, a value based investment management firm.

Matthew Moberg


Start Date

Tenure

Tenure Rank

Feb 25, 2020

2.26

2.3%

Moberg is a Vice President, Portfolio Manager and Research Analyst of Franklin Advisers, Inc. He provides research and advice on the purchases and sales of individual securities, and portfolio risk assessment. He joined Franklin Templeton Investments in 1998. Moberg holds the Certified Public Accountant designation. Mr. Moberg earned his B.A. in history from Washington and Lee University and an M.B.A. with distinction from the University of Michigan.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.02 24.72 7.88 0.25